OpGen (NASDAQ:OPGN) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a report issued on Sunday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Stock Performance

OPGN opened at $3.04 on Friday. The business has a 50 day moving average price of $2.86 and a 200 day moving average price of $4.19. OpGen has a twelve month low of $1.65 and a twelve month high of $38.40.

OpGen (NASDAQ:OPGN) last issued its quarterly earnings results on Monday, July 8th. The medical research company reported $0.21 EPS for the quarter. The company had revenue of $0.17 million for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 997.34%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp acquired a new stake in shares of OpGen, Inc. (NASDAQ:OPGN) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned 2.63% of OpGen at the end of the most recent quarter. Hedge funds and other institutional investors own 2.68% of the company’s stock.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.